



## ASX ANNOUNCEMENT

### Investor Briefing Invitation

**MELBOURNE, Australia (16 July 2025)** – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite shareholders and investors to attend a Company webinar today, Wednesday, 16 July at 11:00am (AEST), to discuss the recently announced exclusive U.S. distribution agreement for FebriDx with PHASE Scientific.

During the briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Commercial Operations PHASE Scientific, Bob Gergen, will provide an overview. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_7ZVirt\\_ySem8LeRPk5D5EQ](https://us02web.zoom.us/webinar/register/WN_7ZVirt_ySem8LeRPk5D5EQ)

Once the registration form is completed, participants will receive a confirmation email with details on how to access the briefing.

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com).*

## Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### Media Contacts:

Haley Chartres – Australia  
H^CK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

### Investor Contact:

George Kopsiaftis  
IR Specialist, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 409 392 687

### Company Registered Office:

Lumos Diagnostics Holdings Ltd  
Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000 Australia  
+61 3 9087 1598